THU0163 A DESCRIPTIVE ANALYSIS OF LONGITUDINAL CHANGES IN RELATIVE MARKET SHARE PROPORTIONS OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITIS: DATA FROM THE OBRI DATABASE

Background For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next step in goal-directed therapy is initiation of either biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs). bDMARDs include tumour-necrosis factor inhibitors (TNFi) or non-TNFi classes. Since inception of Ontario Best Practice Research …